Cisatracurium Besylate Injection
Hospira, Inc., a Pfizer Company
Open FDA's page for this record- Discontinued date
- 09/11/2026
- Update type
- New
- Initial posting date
- 09/11/2026
- Package NDC
- 0409-1098-02
- Generic name
- Cisatracurium Besylate Injection
- Contact info
- 844-646-4398
- Related info
- Supply expected to exhaust November 2026; Discontinuation of the manufacture of the drug
- Update date
- 09/11/2026
- Dosage form
- Injection
- Presentation
- Cisatracurium Besylate, Injection, 10 mg/5ml (2 mg/mL) Single Dose Vial (NDC 0409-1098-02)
- Company name
- Hospira, Inc., a Pfizer Company
- Status
- To Be Discontinued
- Therapeutic category
- Analgesia/Addiction
- Harmonized identifiers (openFDA)
- Application number
- ANDA203236
- Brand name
- CISATRACURIUM BESYLATE
- Generic name
- CISATRACURIUM BESYLATE
- Manufacturer name
- Hospira, Inc.
- Product NDC
- 0409-1098, 0409-1103, 0409-1208
- Product type
- HUMAN PRESCRIPTION DRUG
- Route
- INTRAVENOUS
- Substance name
- CISATRACURIUM BESYLATE
- RxCUI
- 199211, 199212, 1730194
- SPL ID
- 7b64e51a-1a55-4949-ac7c-b0a21cbd6ec9
- SPL set ID
- 67908e20-044d-454d-9c51-bf106e817bd0
- Package NDC
- 0409-1098-12, 0409-1098-02, 0409-1103-11, 0409-1103-01, 0409-1208-11, 0409-1208-01
- UNII
- 80YS8O1MBS